Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• T-cells are vital for tumor immunity, and tumor-infiltrating lymphocytes predict patient prognosis and response to immune checkpoint blockade.
• Chimeric antigen receptor (CAR) T-cell therapy is a promising approach for tumors lacking immune infiltrate or with downregulated antigen presentation.
• CAR T-cell therapy has shown success in hematological tumors but faces challenges in solid tumors due to the tumor microenvironment (TME).

Purpose of the Study:

• To explore the challenges faced by CAR T-cells in solid tumors.
• To highlight the emerging role of metabolic barriers in the TME.
• To discuss strategies for overcoming these barriers to improve CAR T-cell efficacy.

Main Methods:

• Review of current literature on CAR T-cell therapy, tumor immunity, and the TME.
• Analysis of factors hindering CAR T-cell function in solid tumors, including immune suppressive cells and metabolic competition.
• Exploration of potential strategies for enhancing CAR T-cell therapy.

Main Results:

• Solid tumors present significant obstacles to CAR T-cells, including homing issues, vascular barriers, and stromal resistance.
• Protumoral immune cells and metabolic barriers (e.g., nutrient competition) in the TME impair CAR T-cell function, leading to exhaustion.
• CAR T-cell expansion protocols, improved receptor design, and combination immunotherapies show promise in overcoming TME-induced limitations.

Conclusions:

• Metabolic barriers in the TME are a critical factor limiting CAR T-cell efficacy against solid tumors.
• Optimizing CAR T-cell phenotypes, receptor design, and employing immunomodulatory therapies are key strategies to overcome these barriers.
• These advancements hold promise for the successful treatment of solid tumors using CAR T-cell therapy.